Wenting Du

机构：Sun Yat-sen University, Biomarker Technologies (China), Sun Yat-sen University Cancer Center · ORCID：0000-0001-6765-0129

发表论文 230 篇 · 总被引 2663 次 · h-index 28

代表论文

PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis (2026 · Clinical Cancer Research · 被引 1)
Data from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis (2026)
Supplementary Figure S3 from Oncogenic KRAS-Dependent Stromal Interleukin-33 Directs the Pancreatic Microenvironment to Promote Tumor Growth (2026)
Supplementary Table S1 from Oncogenic KRAS-Dependent Stromal Interleukin-33 Directs the Pancreatic Microenvironment to Promote Tumor Growth (2026)
Supplementary Figure S4 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis (2026)
Supplementary Figure S6 from Oncogenic KRAS-Dependent Stromal Interleukin-33 Directs the Pancreatic Microenvironment to Promote Tumor Growth (2026)